M. Marx

发表

Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design.

D. Knighton, K. Liu, M. Yin, 2010, ACS medicinal chemistry letters.

Abstract LB-302: Activity of PF-04691502, A dual PI3K/mTOR inhibitor in breast cancer cell lines and models discriminates between ER, PR and HER2 positive and negative segments

K. Ching, A. Pavlícek, J. Christensen, 2010 .

Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo Activity.

J. Blake, J. Christensen, B. Brandhuber, 2018, ACS medicinal chemistry letters.

Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein–Protein Interaction

J. Christensen, J. Lawson, Jacob R. Haling, 2022, Journal of medicinal chemistry.

Small-molecule, tubulin-binding compounds as vascular targeting agents

M. Marx, 2002 .

Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer

J. Blake, J. Christensen, G. Vigers, 2020 .

Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor

Ella T. Lifset, J. Fernandez-Banet, A. Pavlícek, 2022, Nature Medicine.

4-methylpteridinones as orally active and selective PI3K/mTOR dual inhibitors.

D. Knighton, M. Nambu, K. Liu, 2010, Bioorganic & medicinal chemistry letters.

Cross-Coupling Methods for the Large-Scale Preparation of an Imidazole−Thienopyridine: Synthesis of [2-(3-Methyl-3H-imidazol-4-yl)- thieno[3,2-b]pyridin-7-yl]-(2-methyl-1H-indol-5-yl)-amine

Brian P. Jones, M. Munchhof, Jeffrey M. Casavant, 2003 .

Design and SAR of thienopyrimidine and thienopyridine inhibitors of VEGFR-2 kinase activity.

M. Munchhof, Jonathan L. Doty, Jianmin Sun, 2004, Bioorganic & medicinal chemistry letters.

Highly Selective and Potent Thiophenes as PI3K Inhibitors with Oral Antitumor Activity.

G. Paderes, N. Sach, K. Liu, 2011, ACS medicinal chemistry letters.

Synthetic Design for Combinatorial Chemistry. Solution and Polymer-Supported Synthesis of Polycyclic Lactams by Intramolecular Cyclization of Azomethine Ylides

P. Bartlett, M. Marx, A. Grillot, 1997 .

Atropisomeric Racemization Kinetics of MRTX1719 Using Chiral Solvating Agent-Assisted 19F NMR Spectroscopy

S. D. De Paul, T. Peakman, M. Marx, 2022, ACS omega.

Discovery and synthesis of novel 4-aminopyrrolopyrimidine Tie-2 kinase inhibitors for the treatment of solid tumors.

Tracey Clark, Matthew D. Wessel, R. D. Connell, 2013, Bioorganic & medicinal chemistry letters.

Total synthesis of (+)-ambruticin S.

M. Schneider, S. Martin, T. Kirkland, 2001, Journal of the American Chemical Society.

Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy.

F. Rastinejad, W. Roberts, Eugenia Floyd, 2003, Cancer research.

Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of MTAP-Deleted Cancers.

J. Christensen, J. Lawson, P. Olson, 2022, Journal of medicinal chemistry.

Design of selective, ATP-competitive inhibitors of Akt.

Tracey Clark, Matthew Marx, Blaise Lippa, 2010, Journal of medicinal chemistry.

Identification of MRTX1133, a Noncovalent, Potent, and Selective KRASG12D Inhibitor.

J. Blake, J. Christensen, J. Lawson, 2021, Journal of medicinal chemistry.

The KRASG12C Inhibitor, MRTX849, Provides Insight Toward Therapeutic Susceptibility of KRAS Mutant Cancers in Mouse Models and Patients.

J. Fernandez-Banet, A. Pavlícek, J. Christensen, 2019, Cancer discovery.

Discovery of novel, potent, and selective inhibitors of 3-phosphoinositide-dependent kinase (PDK1).

S. Kazmirski, M. Hickey, G. Alton, 2011, Journal of medicinal chemistry.

Discovery of the highly potent PI3K/mTOR dual inhibitor PF-04691502 through structure based drug design

D. Knighton, M. Edwards, S. Bagrodia, 2010 .

Fragment optimization and elaboration strategies – the discovery of two lead series of PRMT5/MTA inhibitors from five fragment hits

J. Christensen, J. Lawson, Misbha Ud Din Ahmad, 2022, RSC medicinal chemistry.

Design and evaluation of achiral, non-atropisomeric 4-(aminomethyl)phthalazin-1(2H)-one derivatives as novel PRMT5/MTA inhibitors.

J. Christensen, P. Olson, A. Ivetac, 2022, Bioorganic & medicinal chemistry.

Mitotic Checkpoint Kinase Mps1 Has a Role in Normal Physiology which Impacts Clinical Utility

Zhou Zhu, S. Murphy, Sergei L Timofeevski, 2015, PloS one.

Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer.

G. Vigers, J. Gaudino, Jennifer N. Otten, 2020, Journal of medicinal chemistry.

Stereoselective Amine Synthesis Mediated by a Zirconocene Hydride to Accelerate a Drug Discovery Program

John M. Ketcham, M. Marx, Kersti Caddell Haatveit, 2024, The Journal of organic chemistry.